Pricing Log in Create free account
Saturday 17 October 2026 Export ADIL’s income statement to Excel — free account

Adial Pharmaceuticals, Inc.

ADIL Healthcare Biotechnology

In the quarter to June 2026, EPS fell 150.0% and free cash flow fell 263.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.49 0.35 +11.15%
Market cap
$8.3M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Adial Pharmaceuticals, Inc. (ADIL) Business Profile

Updated before January 2025

Company Overview

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) is a clinical-stage biopharmaceutical company dedicated to the development of treatments for addiction and related disorders. Founded in 2010 and headquartered in Charlottesville, Virginia, Adial focuses on addressing unmet medical needs in the addiction treatment space. The company was established by Dr. William Stilley, who also serves as its Chief Executive Officer. Under his leadership, Adial has been at the forefront of developing innovative therapies aimed at improving the lives of individuals struggling with addiction.

Adial’s mission is to provide effective, non-addictive treatments for addiction, a field that has historically been underserved. The company’s flagship product, AD04, is a genetically targeted therapeutic designed to treat alcohol use disorder (AUD). Adial’s leadership team includes experienced professionals with backgrounds in pharmaceuticals, biotechnology, and clinical research, ensuring a robust foundation for its operations and strategic direction.

Core Business Segments

Adial Pharmaceuticals operates primarily in the biopharmaceutical sector, with a focus on addiction treatment. Its core business segments include:

1. Addiction Treatment Therapies

  • AD04: Adial’s lead product candidate, AD04, is a genetically targeted oral therapeutic designed to treat alcohol use disorder (AUD). Unlike traditional treatments, AD04 is non-addictive and has a favorable safety profile. It is currently undergoing clinical trials to evaluate its efficacy and safety.
  • Pipeline Development: Adial is also exploring the potential of AD04 for treating other addiction-related disorders, such as opioid use disorder and gambling addiction.

2. Diagnostic Tools

  • Genetic Testing: Adial offers genetic testing services to identify patients who are most likely to benefit from AD04. This personalized approach enhances treatment outcomes and aligns with the company’s commitment to precision medicine.

Business Model

Adial Pharmaceuticals employs a business model centered on innovation, clinical development, and strategic partnerships. The company generates revenue through:

  • Clinical Development: Advancing its lead product candidate, AD04, through clinical trials and regulatory approval processes.
  • Licensing Agreements: Partnering with pharmaceutical companies to commercialize AD04 and other pipeline products in global markets.
  • Genetic Testing Services: Offering genetic testing as a complementary service to its therapeutic products, creating an integrated treatment ecosystem.

Adial’s approach combines cutting-edge science with a patient-centric focus, ensuring that its products address the specific needs of individuals struggling with addiction.

Strategic Direction

Adial Pharmaceuticals is committed to expanding its footprint in the addiction treatment market. Key strategic initiatives include:

  • Advancing Clinical Trials: Completing Phase 3 clinical trials for AD04 and pursuing regulatory approvals in the United States and Europe.
  • Expanding Indications: Exploring the potential of AD04 for treating other addiction-related disorders, such as opioid use disorder and binge eating disorder.
  • Global Partnerships: Establishing strategic alliances with pharmaceutical companies to commercialize AD04 in international markets.
  • Sustainability Goals: Incorporating environmentally sustainable practices in its operations and supply chain management.
  • Innovation in Diagnostics: Enhancing its genetic testing capabilities to support personalized medicine initiatives.

Competitive Landscape

Adial Pharmaceuticals operates in a competitive biopharmaceutical market, facing competition from companies developing treatments for addiction and related disorders. Key competitors include:

  • Alkermes plc: Known for its addiction treatment products, such as Vivitrol for alcohol and opioid dependence.
  • Indivior PLC: A leader in opioid addiction treatments, offering products like Suboxone.
  • Opiant Pharmaceuticals: Focused on developing treatments for opioid overdose and addiction.
  • Pear Therapeutics: Specializes in digital therapeutics for substance use disorders.

Adial differentiates itself through its genetically targeted approach and focus on non-addictive therapies, positioning it as a unique player in the addiction treatment market.

Risk Factors

Adial Pharmaceuticals faces several risks that could impact its operations and financial performance:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals for AD04 could hinder commercialization efforts.
  • Market Dependence: Reliance on a single product candidate, AD04, increases vulnerability to market and clinical trial outcomes.
  • Competition: Intense competition from established players in the addiction treatment market could limit market share.
  • Supply Chain Disruptions: Challenges in sourcing raw materials or manufacturing AD04 could delay product availability.
  • Financial Risks: As a clinical-stage company, Adial relies on external funding and may face challenges in securing adequate capital.

Recent Developments

Adial Pharmaceuticals has made significant progress in recent years, including:

  • Clinical Trial Advancements: Completion of key milestones in the Phase 3 clinical trials for AD04, demonstrating promising efficacy and safety results.
  • Regulatory Submissions: Initiating regulatory submissions in the United States and Europe for AD04.
  • Partnerships: Establishing collaborations with genetic testing companies to enhance its diagnostic capabilities.
  • COVID-19 Impact: Navigating challenges posed by the COVID-19 pandemic, including disruptions to clinical trials and supply chains.

Investment Considerations

Investors considering Adial Pharmaceuticals should weigh the following factors:

Strengths

  • Innovative Product Pipeline: AD04’s genetically targeted approach offers a unique value proposition in the addiction treatment market.
  • Experienced Leadership: A seasoned management team with expertise in pharmaceuticals and clinical research.
  • Market Potential: Significant unmet medical needs in addiction treatment create growth opportunities.

Risks

  • Regulatory Uncertainty: Dependence on successful regulatory approvals for AD04.
  • Financial Constraints: Reliance on external funding to support clinical development and operations.
  • Market Competition: Intense competition from established players in the addiction treatment space.

Conclusion

Adial Pharmaceuticals, Inc. is a pioneering biopharmaceutical company focused on addressing the global addiction crisis. With its innovative product pipeline, commitment to precision medicine, and strategic partnerships, Adial is well-positioned to make a significant impact in the addiction treatment market. While challenges remain, including regulatory and financial risks, the company’s unique approach and market potential make it an attractive prospect for investors seeking exposure to the biopharmaceutical sector.